System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Axel Hauschild is an expert in Oncology at University Hospital Schleswig-Holstein (Germany). As of October 2026, ScienceLeadR ranks Axel Hauschild in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Carcinoma. Axel Hauschild has authored 703 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 1 of them ongoing. SLR score: 2,632 (community average: 125). How the SLR is computed.

LeadR Profile

Axel Hauschild University Hospital Schleswig-Holstein Germany
2 632 ScienceLeadR Reputation 2632

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

University Hospital Schleswig-Holstein

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 703

Citations

Citations: 66 942 1st author: 96 Last author: 119 Unique author: 20

Main journals

J Clin Oncol 102
Eur J Cancer 94
Ann Oncol 66
J Dtsch Dermatol Ges 58
Hautarzt 27

Best Journals

J Clin Oncol 26
Lancet Oncol 24
Ann Oncol 20

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis.
PMID 42921711 — cells, carcinoma, squamous cell, medical oncology, cutaneous squamous cell carcinoma		J Clin Oncol Top journal20260
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
PMID 42579833 — safety, melanoma, therapeutics		J Clin Oncol Top journal20262
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
PMID 42501621 — safety, melanoma, therapeutics, mutation		Eur J Cancer20260
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.
PMID 42393046 — registries, biological science disciplines, probability, melanoma, neoplasms, diagnosis, prospective studies		Nat Commun20262
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
PMID 42263355 — radiotherapy, cells, carcinoma, squamous cell, neoplasms, therapeutics, cutaneous squamous cell carcinoma		Eur J Cancer20260

Clinical Studies 45

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 26
Phase 2 15
N/A 1
Phase 1 1
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 31
Active not recruiting 5
Terminated 4
Unknown 4
Recruiting 1

By type:

Interventional 44
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 41

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Adjuvant Encorafenib and Binimetinib in High risk Stage II Melanoma With a BRAF Mutation
NCT05270044 — melanoma, placebos, tablets, capsules, mutation		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS